ArticleFrontiers in medicine2025
The diagnostic value of C-X-C motif chemokine 8 in elderly patients with bacterial upper respiratory tract infections and its correlation with prognosis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to further investigate the correlation between C-X-C motif chemokine 8 (CXCL8) and the prognosis of bacterial upper respiratory tract infections (BURTIs) in the elderly population (≥65 years) and to evaluate its potential as a clinical biomarker in this specific high-risk cohort. Methods: A total of 58 elderly patients with BURTIs admitted to our hospital between January 2023 and June 2023 (observation group) and 42 healthy individuals (control group) who underwent physical examinations concurrently were selected as the research subjects. Peripheral blood CXCL8 levels were measured in both the observation and control groups at admission and reassessed in the observation group after treatment to determine differences in CXCL8 between groups and changes in CXCL8 before and after treatment in the observation group. The correlation of CXCL8 with BURTI clinical effectiveness was analyzed. Subsequently, BURTI patients were followed up for 1 year, and the effect of post-treatment CXCL8 expression on the prognostic recurrence of BURTIs was evaluated. Results: The CXCL8 in the observation group was higher than that in the control group (89.67 ± 8.33 pg./mL Conclusion: CXCL8 is elevated in elderly patients with BURTIs, demonstrating good evaluation effects on the occurrence and prognostic recurrence of BURTIs. However, these findings position CXCL8 as a promising biomarker for guiding personalized treatment in elderly BURTI patients, though further validation and integration with clinical scores are needed to improve risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.